Patent US2409783A successfully refreshed from Google Patents.
US4935233A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Covalently linked polypeptide cell modulators
Assignee: GD Searle LLC
•
Filing: 1985-12-02
•
Granted: 1990-06-19
•
Expires: 2005-12-02
Abstract
Abstract Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides have new and particularly useful activities when the component polypeptide cell modulators are interferons, lymphokines or cytotoxins which act through different and specific cell receptors to initiate complementary biological activities.
Inventors
- 👤 Leslie D. Bell
- 👤 Keith G. McCullagh
- 👤 Alan G. Porter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:37
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; A; A61; A61P; A61P31/00; A61P31/12; A61P35/00; A61P37/00; C07K14/475; C07K14/555; C07K14/565; C07K14/57; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C12N15/63; C12N15/70; A61K; A61K38/00; C07K2319/00; C07K2319/55; C07K2319/70; C07K2319/74; C07K2319/75; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142; Y10S930/143
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
47 words
A composition represented by the formula R.sub.1 --L--R.sub.2 wherein R 1 is gamma interferon or a biologically active modified gamma interferon; R 2 is beta interferon or a biologically active modified beta interferon; and L is a peptide linker segment of 1 to 500 amino acid residues.
Claim 2
Dependent Claim
47 words
A composition represented by the formula R.sub.1 --L--R.sub.2 wherein R 1 is gamma interferon or a biologically active modified gamma interferon; R 2 is beta interferon or a biologically active modified beta interferon; and L is a peptide linker segment of 1 to 500 amino acid residues.
Claim 3
Dependent Claim
38 words
A composition according to claim 1 wherein R 1 is gamma interferon and R 2 is a modified beta interferon wherein amino acids 36-48 of natural beta interferon have been replaced by amino acids 34-46 of alpha interferon.
Claim 4
Dependent Claim
53 words
A composition according to claim 1 wherein R 1 is gamma interferon and R 2 is a modified beta interferon wherein amino acids of 36-48 of natural beta interferon have been replaced by amino acids 34-46 of alpha interferon and the cysteine at position 17 of natural beta interferon is replaced by serine.
Claim 5
Dependent Claim
25 words
The protein identified in FIG. 8 and FIG. 9 as IFNX 601 and having the amino acid sequence shown in FIG. 8 and FIG. 9.
Claim 6
Dependent Claim
25 words
The protein identified in FIG. 8 and FIG. 9 as IFNX 601 and having the amino acid sequence shown in FIG. 8 and FIG. 9.
Claim 7
Dependent Claim
25 words
The protein identified in FIG. 10 and FIG. 11 as IFNX 602 and having the amino acid sequence shown in FIG. 10 and FIG. 11.
Claim 8
Dependent Claim
25 words
The protein identified in FIG. 10 and FIG. 11 as IFNX 602 and having the amino acid sequence shown in FIG. 10 and FIG. 11.
Claim 9
Dependent Claim
39 words
A pharmaceutical composition for use in the treatment of viral infections, regulating cell growth or regulating the immune system in an animal comprising a therapeutically effective amount of the composition of claim 1 admixed with a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
39 words
A pharmaceutical composition for use in the treatment of viral infections, regulating cell growth or regulating the immune system in an animal comprising a therapeutically effective amount of the protein of claim 4 admixed with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
39 words
A pharmaceutical composition for use in the treatment of viral infections, regulating cell growth or regulating the immune system in an animal comprising a therapeutically effective amount of the protein of claim 5 admixed with a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
28 words
A method of treating viral infections in an animal in need of such treatment comprising the administration of an effective therapeutic amount of the protein of claim 4.
Claim 13
Dependent Claim
28 words
A method of regulating cell growth in an animal in need of such treatment comprising the administration of an effective therapeutic amount of the protein of claim 4.
Claim 14
Dependent Claim
29 words
A method of regulating the immune system in an animal in need of such treatment comprising the administration of an effective therapeutic amount of the protein of claim 4.
Claim 15
Dependent Claim
28 words
A method of treating viral infections in an animal in need of such treatment comprising the administration of an effective therapeutic amount of the protein of claim 5.
Claim 16
Dependent Claim
28 words
A method of regulating cell growth in an animal in need of such treatment comprising the administration of an effective therapeutic amount of the protein of claim 5.
Claim 17
Dependent Claim
29 words
A method of regulating the immune system in an animal in need of such treatment comprising the administration of an effective therapeutic amount of the protein of claim 5.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-18 | 1993-12-18 | 1994-06-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-18 | 1997-12-18 | 1998-06-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-18 | 2001-12-18 | 2002-06-19 | $7700.00 | Window Closed / Lapsed |